J. Dennis

First name
J.
Middle name
M.
Last name
Dennis
Güdemann, L. M., Young, K. G., Thomas, N. J. M., Hopkins, R., Challen, R., Jones, A. G., et al. (2024). Safety and effectiveness of SGLT2 inhibitors in a UK population with type 2 diabetes and aged over 70 years: an instrumental variable approach. Diabetologia. http://doi.org/10.1007/s00125-024-06190-9
View
Hopkins, R., Young, K. G., Thomas, N. J., Godwin, J., Raja, D., Mateen, B. A., et al. (2024). Risk factor associations for severe COVID-19, influenza and pneumonia in people with diabetes to inform future pandemic preparations: UK population-based cohort study. Bmj Open, 14, e078135. http://doi.org/10.1136/bmjopen-2023-078135
View
Venkatasubramaniam, A., Mateen, B. A., Shields, B. M., Hattersley, A. T., Jones, A. G., Vollmer, S. J., & Dennis, J. M. (2023). Comparison of causal forest and regression-based approaches to evaluate treatment effect heterogeneity: an application for type 2 diabetes precision medicine. Bmc Med Inform Decis Mak, 23, 110. http://doi.org/10.1186/s12911-023-02207-2
View
Dennis, J. M., Young, K. G., McGovern, A. P., Mateen, B. A., Vollmer, S. J., Simpson, M. D., et al. (2022). Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study. Lancet Digit Health, 4, e873-e883. http://doi.org/10.1016/s2589-7500(22)00174-1
View
Dennis, J. M., Henley, W. E., Weedon, M. N., Lonergan, M., Rodgers, L. R., Jones, A. G., et al. (2018). Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. Diabetes Care. http://doi.org/10.2337/dc18-0344
View
Curtis, H. J., Dennis, J. M., Shields, B. M., Walker, A. J., Bacon, S., Hattersley, A. T., et al. (2018). Time trends and geographical variation in prescribing of drugs for diabetes in England from 1998 to 2017. Diabetes Obes Metab. http://doi.org/10.1111/dom.13346
View
Dennis, J. M., Shields, B. M., Hill, A. V., Knight, B. A., McDonald, T. J., Rodgers, L. R., et al. (2018). Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. Diabetes Care. http://doi.org/10.2337/dc17-1827
View
Dennis, J. M., Henley, W. E., McGovern, A. P., Farmer, A. J., Sattar, N., Holman, R. R., et al. (2019). Time trends in prescribing of type 2 diabetes drugs, glycemic response and risk factors: a retrospective analysis of primary care data, 2010-2017. Diabetes Obes Metab. http://doi.org/10.1111/dom.13687
View
McGovern, A. P., Dennis, J. M., Shields, B. M., Hattersley, A. T., Pearson, E. R., & Jones, A. G. (2019). What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study. BMC Med. http://doi.org/10.1186/s12916-019-1307-8
View
McGovern, A. P., Hogg, M., Shields, B. M., Sattar, N. A., Holman, R. R., Pearson, E. R., et al. (2020). Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Res Care. http://doi.org/10.1136/bmjdrc-2020-001238
View